SCHEMBL29628224

SCHEMBL29628224

N=C(N)NCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 11/20 0.51
▸ NPY1R P25929 6/20 0.51
▸ NPY2R P49146 4/20 0.51
▸ NPY5R Q15761 4/20 0.51
▸ GNPAT O15228 1/20 0.48
▸ KISS1R Q969F8 1/20 0.47
▸ FNTA P49354 3/20 0.46
▸ FNTB P49356 3/20 0.46
▸ PGGT1B P53609 3/20 0.46
▸ FOLH1 Q04609 2/20 0.46
▸ MME P08473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31154635 0.99 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29628380 0.98 NPY4R (0.54) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29628208 0.97 NPY4R (0.52) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29628241 0.95 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL29628189 0.95 NPY4R (0.54) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL30401538 0.95 NPY4R (0.55) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29403792 0.94 FOLH1 (0.52) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29628209 0.94 NPY4R (0.52) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL30866590 0.93 NPY4R (0.56) NPY4RNPY1RNPY2RNPY5RKISS1R
SCHEMBL23142771 0.93 NPY4R (0.58) NPY4RNPY1RNPY2RNPY5RGNPAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127939-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY PURDUE RESEARCH FOUNDATION 2025-04-24 — — US disclosed
EP-4541378-A2 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY Endocyte, Inc. (US) 2025-04-23 — — EP disclosed
US-12178892-B2 Compounds for positron emission tomography PURDUE RESEARCH FOUNDATION (US) 2024-12-31 — — US disclosed
US-20220125958-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY PURDUE RESEARCH FOUNDATION 2022-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127939-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY VHL, PC, NPC1 NPY4R 4297/4885NPY1R 4092/4885NPY2R 4312/4885
US-12178892-B2 Compounds for positron emission tomography FOLH1, FOLR2, FOLR1 NPY4R 2363/4885NPY1R 1152/4885NPY2R 1595/4885
US-20220125958-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY FOLH1, FOLR2, FOLR1 NPY4R 2363/4885NPY1R 1152/4885NPY2R 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback